- Home
- FOLD vs CWEN Comparison
FOLD vs CWEN Comparison
Compare FOLD & CWEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- CWEN
- Stock Information
- Founded
- FOLD 2002
- CWEN 2012
- Country
- FOLD United States
- CWEN United States
- Employees
- FOLD N/A
- CWEN N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- CWEN Electric Utilities: Central
- Sector
- FOLD Health Care
- CWEN Utilities
- Exchange
- FOLD Nasdaq
- CWEN Nasdaq
- Market Cap
- FOLD 2.9B
- CWEN 3.4B
- IPO Year
- FOLD 2007
- CWEN 2013
- Fundamental
- Price
- FOLD $6.16
- CWEN $30.36
- Analyst Decision
- FOLD Buy
- CWEN Strong Buy
- Analyst Count
- FOLD 10
- CWEN 4
- Target Price
- FOLD $16.22
- CWEN $35.75
- AVG Volume (30 Days)
- FOLD 5.0M
- CWEN 863.2K
- Earning Date
- FOLD 05-01-2025
- CWEN 04-30-2025
- Dividend Yield
- FOLD N/A
- CWEN 5.64%
- EPS Growth
- FOLD N/A
- CWEN 20.79
- EPS
- FOLD N/A
- CWEN 0.79
- Revenue
- FOLD $543,141,000.00
- CWEN $1,406,000,000.00
- Revenue This Year
- FOLD $19.85
- CWEN $7.88
- Revenue Next Year
- FOLD $23.50
- CWEN $10.82
- P/E Ratio
- FOLD N/A
- CWEN $38.17
- Revenue Growth
- FOLD 28.25
- CWEN 9.08
- 52 Week Low
- FOLD $5.81
- CWEN $24.02
- 52 Week High
- FOLD $12.65
- CWEN $31.09
- Technical
- Relative Strength Index (RSI)
- FOLD 41.91
- CWEN 55.75
- Support Level
- FOLD $6.03
- CWEN $30.13
- Resistance Level
- FOLD $6.37
- CWEN $31.02
- Average True Range (ATR)
- FOLD 0.24
- CWEN 0.69
- MACD
- FOLD 0.04
- CWEN 0.06
- Stochastic Oscillator
- FOLD 41.67
- CWEN 74.90
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.